To value the use of anti-DR4 or anti-DR5 moAbs for cancer therapy, and to strengthen their pro-apoptotic potential, other rational approaches have been set up, such as increasing their valency or combining them with TRAIL [146,147,148]. This evidence concerns the gene TNFRSF10B and cancer.